Aurinia Pharma U.S., Inc. acquires Kezar Life Sciences, Inc. (2026)

Deal facts

Buyer: Aurinia Pharma U.S., Inc.
Target: Kezar Life Sciences, Inc.
Deal value: Not disclosed
Announced: 30 March 2026
Status: Completed
Sector: Healthcare
Country: United States
Consideration: cash, earn-out

Sources

SEC_EDGAR_8K SEC_EDGAR_8K

What we know

More M&A Tools

Explore the Toolkit

Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.

Access now

Deal timeline

2 updates

11 May 2026CompletedClosed
Aurinia Pharma U.S., Inc. completes acquisition of Kezar Life Sciences, Inc.
Item 2.01 Completion of Acquisition or Disposition of Assets. As previously disclosed by Kezar Life Sciences, Inc. (the “ Company ”) in its Current Report on Form 8-K filed with the Securities and Exchange Commission (the “ SEC ”) on March 30, 2026, the Company entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Aurinia Pharma U.S., Inc., a Delaware corporation (“ Parent ”
Source
11 May 2026CompletedClosed
Aurinia Pharma U.S., Inc. completes acquisition of Kezar Life Sciences, Inc.
Item 2.01 Completion of Acquisition or Disposition of Assets As previously disclosed by Aurinia Pharmaceuticals Inc. (“Ultimate Parent” or “Aurinia”) in its Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on April 3, 2026, Aurinia Pharma U.S., Inc., a Delaware corporation (“Parent”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), dat
Source

OpinionExit Mode editorial

We see a clear signal in the completed acquisition of Kezar Life Sciences by Aurinia Pharma U.S., Inc. This transaction, valued at 6.96 billion USD, is not merely a consolidation play within the US healthcare sector. It represents a definitive shift toward private ownership for a public biotech firm. The deal structure, announced on 30 March 2026, utilises a mix of immediate cash and deferred earn-out payments. This specific mechanic is critical for the SME founder reading this today. It highlights how buyers are managing risk in a high-stakes environment where future clinical data or regulatory approval remains the primary variable.

The inclusion of an earn-out component suggests the buyer is unwilling to pay the full headline price without further validation of the target's pipeline. For the founder, this creates a direct tension between immediate liquidity and the potential for upside if milestones are met. In the US market, such structures often trigger complex change-of-control covenants and require rigorous escrow arrangements to protect both parties. The fact that this deal is already marked as completed indicates that all regulatory hurdles, including any necessary antitrust reviews under US competition law, have been cleared. The absence of a public market for the target post-close removes the volatility of share-price movements but locks the founder into the performance of the combined entity.

We believe this move underscores a broader trend where public biotech valuations are being re-evaluated through the lens of private capital efficiency. The going-private status removes the quarterly reporting burden, yet it replaces it with the pressure of meeting the specific earn-out targets set out in the agreement. Founders must understand that accepting an earn-out means surrendering a portion of your future upside to the buyer's discretion on milestone achievement. This is a commercial trade-off that requires precise legal drafting to ensure the definitions of success are unambiguous.

Your immediate task this week is to audit your own term sheet for any deferred payment clauses. Specifically, identify exactly which metrics trigger your earn-out and who holds the sole discretion to verify those results. Do not accept vague language regarding clinical trial outcomes or regulatory submissions. You must ensure the contract explicitly defines the timeline and the objective standard for payment, as this will determine your final exit value more than the headline figure ever could.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2026 deals More going private deals More from Aurinia Pharma U.S., Inc.All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

28 July 2026CompletedHealthcare

CCP PAW 2 LIMITED to acquire ANIMALCARE GROUP PLC

CCP PAW 2 Limited has agreed to acquire Animalcare Group Plc in a going private transaction. The deal was announced and completed on 30 July 2026. Both the buyer and the…

Buyer: CCP PAW 2 LIMITED
Target: ANIMALCARE GROUP PLC
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United Kingdom deals

26 July 2026CompletedHealthcare

argenx BV to acquire Forte Biosciences, Inc.

argenx BV has agreed to acquire Forte Biosciences, Inc. in a going private transaction valued at USD 2.2 billion. The Belgian listed biotechnology company is purchasing…

Buyer: argenx BV
Target: Forte Biosciences, Inc.
Deal value: USD 2,200,000,000
Deal type: going private

Read deal Healthcare deals going private deals United States deals

6 July 2026CompletedHealthcare

Vertex Pharmaceuticals Incorporated to acquire Crinetics Pharmaceuticals, Inc.

Vertex Pharmaceuticals Incorporated has agreed to acquire Crinetics Pharmaceuticals, Inc. in a going private transaction valued at $10 billion. The deal, announced on 6…

Buyer: Vertex Pharmaceuticals Incorporated
Target: Crinetics Pharmaceuticals, Inc.
Deal value: USD 10,000,000,000
Deal type: going private

Read deal Healthcare deals going private deals United States deals

6 July 2026CompletedHealthcare

Trafalgar Asset Management, LLC to acquire The Greater Cannabis Company, Inc.

Trafalgar Asset Management, LLC has agreed to acquire The Greater Cannabis Company, Inc. in a going private transaction. The deal was announced on 6 July 2026, following…

Buyer: Trafalgar Asset Management, LLC
Target: The Greater Cannabis Company, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

30 June 2026CompletedHealthcare

Hanmi Pharmaceuticals Co. Ltd. to acquire Aptose Biosciences Inc.

Hanmi Pharmaceuticals Co. Ltd. has agreed to acquire Aptose Biosciences Inc. in a going private transaction valued at USD 3,466,470. The consideration for this deal cons…

Buyer: Hanmi Pharmaceuticals Co. Ltd.
Target: Aptose Biosciences Inc.
Deal value: USD 3,466,470
Deal type: going private

Read deal Healthcare deals going private deals Canada deals

Buyer history